Want to see OCS full AI Analyst Report?
OCS Stock Chart & Stats
$12.96
-$0.13(-1.17%)
At close: 4:00 PM EDT
$12.96
-$0.13(-1.17%)
Day’s Range― - ―
52-Week Range$7.11 - $34.48
Previous CloseN/A
Volume218.36K
Average Volume (3M)293.69K
Market Cap
$462.37M
Enterprise Value$569.93M
Total Cash (Recent Filing)$8.00K
Total Debt (Recent Filing)$2.54M
Price to Earnings (P/E)―
Beta0.98
Next Earnings
Nov 05, 2026EPS Estimate
-0.48Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.40
Shares Outstanding61,732,063
10 Day Avg. Volume334,236
30 Day Avg. Volume293,685
Financial Highlights & Ratios
PEG Ratio0.60
Price to Book (P/B)4.22
Price to Sales (P/S)0.00
P/FCF Ratio-13.27
Enterprise Value/Market Cap1.23
Enterprise Value/Revenue2.35K
Enterprise Value/Gross Profit6.66K
Enterprise Value/Ebitda-7.27
Forecast
1Y Price Target
$36.43Price Target Upside181.08% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-1.54
Revenue Forecast (FY)$840.86K
Bulls Say, Bears Say
Bulls Say
Strong Balance SheetVery low leverage and a substantial equity base provide financial flexibility while Oculis advances its pipeline. This can support continued development investment and reduce balance-sheet pressure over the next several quarters, although ongoing losses may gradually consume that cushion.
Promising Clinical EvidenceConvergent functional, retinal, and serum biomarker results strengthen the clinical rationale for Privosegtor and support advancement into the PIONEER registrational program. If reproduced in later studies, this evidence could improve regulatory and commercial potential across neuro-ophthalmic indications.
Greater Asset OwnershipFull ownership of Privosegtor and ACT-02 could give Oculis greater control over development, partnering, and future commercialization than its prior license structure. The transaction also removes previous milestone and royalty obligations to Accure, potentially improving long-term economics if programs succeed.
Bears Say
Shrinking Revenue And Deep LossesMinimal and declining revenue shows that Oculis has not yet established a commercial earnings base, while the large net loss reflects substantial development spending. This limits internally funded growth and leaves future financial performance highly dependent on clinical progress and eventual product approval.
Persistent Cash BurnSustained negative operating and free cash flow indicates that Oculis consumes substantial cash to fund its operations and pipeline. Continued burn can reduce the current financial cushion over time and increase reliance on existing liquidity, equity financing, or collaboration proceeds to sustain development.
Pre-commercial Business ModelThe company currently lacks recurring product sales and must advance candidates through clinical development and regulatory approval before building a durable commercial revenue stream. That creates execution risk because future economics depend on successful trials, approvals, launches, and potential financing or partnerships.
Oculis Holding News
OCS FAQ
What was Oculis Holding’s price range in the past 12 months?
Oculis Holding lowest stock price was $7.11 and its highest was $34.48 in the past 12 months.
What is Oculis Holding’s market cap?
Oculis Holding’s market cap is $462.37M.
When is Oculis Holding’s upcoming earnings report date?
Oculis Holding’s upcoming earnings report date is Nov 05, 2026 which is in 13 days.
How were Oculis Holding’s earnings last quarter?
Oculis Holding released its earnings results on Aug 06, 2026. The company reported -$0.192 earnings per share for the quarter, beating the consensus estimate of -$0.466 by $0.274.
Is Oculis Holding overvalued?
According to Wall Street analysts Oculis Holding’s price is currently Undervalued.
Does Oculis Holding pay dividends?
Oculis Holding does not currently pay dividends.
What is Oculis Holding’s EPS estimate?
Oculis Holding’s EPS estimate is -0.48.
How many shares outstanding does Oculis Holding have?
Oculis Holding has 61,732,063 shares outstanding.
What happened to Oculis Holding’s price movement after its last earnings report?
Oculis Holding reported an EPS of -$0.192 in its last earnings report, beating expectations of -$0.466. Following the earnings report the stock price went up 2.423%.
Which hedge fund is a major shareholder of Oculis Holding?
Currently, no hedge funds are holding shares in OCS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Oculis Holding Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$36.43 (181.08% Upside)
$36.43 (181.08% Upside)
Blogger Sentiment
Bullish
OCS Sentiment 100%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 315.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 1.0%
Last 30 Days >0.1%
Last 30 Days >0.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-63.93%
12-Months-Change
Fundamentals
Return on Equity
-42.92%
Trailing 12-Months
Asset Growth
36.01%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Oculis Holding
Oculis Holding AG is a biopharmaceutical company in the clinical development stage, specializing in the creation of innovative eye drop medications for various ocular conditions, addressing both the anterior and posterior segments of the eye. A key asset in its therapeutic portfolio is OCS-01, a topical formulation of dexamethasone, currently progressing through Phase 3 clinical trials for the management of diabetic macular edema. Additionally, OCS-02, a topically administered biological candidate, is engaged in Phase 2b clinical studies to treat keratoconjunctivitis sicca, commonly known as dry eye disease. The company is also advancing OCS-05, an innovative neuroprotective agent, which targets acute optic neuritis and an array of other neuro-ophthalmic disorders, including glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. This enterprise maintains its headquarters in Zug, Switzerland.
OCS Stock 12 Month Forecast
Average Price Target
$36.43
▲(181.08% Upside)
Technical Analysis
Ownership Overview
―
Insiders
1.45% Mutual Funds
0.61% Other Institutional Investors
97.67% Public Companies and
Individual Investors